These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 3922181)

  • 21. [Immunogenic properties of the liposomal form of Pseudomonas aeruginosa anatoxin].
    Minukhin VV; Brodinova NS; Tsyganenko AIa; Ivanova NN; Vasil'chenko VN; Sennikov GA
    Vestn Akad Med Nauk SSSR; 1990; (8):44-7. PubMed ID: 2125778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Immunogenic properties of Clostridium perfringens type A anatheta-hemolysin].
    Sergeeva TI; Dolgikh MS; Blagoveshchenskiĭ VA
    Zh Mikrobiol Epidemiol Immunobiol; 1981 Nov; (11):71-5. PubMed ID: 6275640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity of purified Habu snake-venom toxoid in guinea pigs and monkeys with special reference to HR1 component.
    Sadahiro S; Omori-Satoh T; Yamauchi K; Kondo S; Ishida S; Murata R
    Jpn J Med Sci Biol; 1981 Aug; 34(4):213-30. PubMed ID: 6798252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A comparative evaluation of the pathogenicity factors of Pseudomonas aeruginosa].
    Komzolova NB
    Gig Sanit; 1991 Nov; (11):68-9. PubMed ID: 1667104
    [No Abstract]   [Full Text] [Related]  

  • 25. Evaluation of Pseudomonas aeruginosa toxin A in experimental rat burn wound sepsis.
    Walker HL; McLeod CG; Leppla SH; Mason AD
    Infect Immun; 1979 Sep; 25(3):828-30. PubMed ID: 500188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Experimental infection with Pseudomonas aeruginosa in mice. I. The virulence of Pseudomonas aeruginosa for mice.
    Kobayashi F
    Jpn J Microbiol; 1971 Jul; 15(4):295-300. PubMed ID: 4330067
    [No Abstract]   [Full Text] [Related]  

  • 27. [Use of the passive hemagglutination test for the purpose of determining antibody levels following animal immunization with Cl. perfringens toxoid].
    Shemanova GF; Dmitrieva LN; Vlasova EV; Panteleev EI; Moshiashvili IIa
    Zh Mikrobiol Epidemiol Immunobiol; 1977 Feb; (2):85-8. PubMed ID: 193324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New method of preparing elastase toxoid from Pseudomonas aeruginosa.
    Morihara K; Homma JY
    J Clin Microbiol; 1986 Jan; 23(1):53-5. PubMed ID: 3084545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The roles of various fractions of Pseudomonas aeruginosa in its pathogenesis. 3. Identity of the lethal toxins produced in vitro and in vivo.
    Liu PV
    J Infect Dis; 1966 Oct; 116(4):481-9. PubMed ID: 4959184
    [No Abstract]   [Full Text] [Related]  

  • 30. Neutralizing antibody to Pseudomonas aeruginosa exotoxin in human sera: evidence for in vivo toxin production during infection.
    Pollack M; Callahan LT; Taylor NS
    Infect Immun; 1976 Oct; 14(4):942-7. PubMed ID: 825470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development, preparation and safety testing of a Clostridium welchii type C toxoid. I: preliminary observations in man in Papua New Guinea.
    Walker PD; Foster WH; Knight PA; Freestone DS; Lawrence G
    J Biol Stand; 1979; 7(4):315-23. PubMed ID: 231605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Passive hemagglutination reaction using formalinized sheep erythrocytes treated with tannic acid and coated with exotoxin of Pseudomonas aeruginosa.
    Takeshi K; Homma JY
    Jpn J Exp Med; 1978 Dec; 48(6):497-501. PubMed ID: 108439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pseudomonas aeruginosa exotoxin A and its role in the pathogenesis of pyocyaneus infection].
    Vertiev IuV; Brodinova NS; Moroz AF
    Zh Mikrobiol Epidemiol Immunobiol; 1981 Feb; (2):13-9. PubMed ID: 6787818
    [No Abstract]   [Full Text] [Related]  

  • 34. [Obtaining the homologous hyperimmune preparations from the blood of immunized donors - anti-coli (anti-Escherichia) and antitoxic antipyocyanotic plasma].
    Skurkovich SV; Likhoded VG; Krokhina MA; Temper RM; Demidova NV
    Probl Gematol Pereliv Krovi; 1978 Feb; 23(2):51-3. PubMed ID: 417340
    [No Abstract]   [Full Text] [Related]  

  • 35. Therapeutic effect of immunization with OEP, protease toxoid and elastase toxoid on corneal ulcers in mice due to Pseudomonas aeruginosa infection.
    Hirao Y; Homma JY
    Jpn J Exp Med; 1978 Feb; 48(1):41-51. PubMed ID: 97424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mouse-protection experience with monovalent Pseudomonas aeruginosa vaccine.
    Sourek J; Výmola F; Zelenková L
    Zentralbl Bakteriol A; 1980 Mar; 246(3):353-62. PubMed ID: 6775443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pseudomonas aeruginosa preparations for active immunization].
    Nazarchuk LV
    Vrach Delo; 1991 Jul; (7):22-7. PubMed ID: 1771827
    [No Abstract]   [Full Text] [Related]  

  • 38. [Experimental preventive properties of a complex of Pseudomonas aeruginosa and Clostridium tetani anatoxins].
    Podgornaia LG; Dziuban NF; Kalinichenko NF; Isaeva SIa
    Mikrobiol Zh (1978); 1987; 49(5):55-8. PubMed ID: 3150503
    [No Abstract]   [Full Text] [Related]  

  • 39. Toxoids of Pseudomonas aeruginosa toxin A: production by chemical and genetic means.
    Cryz SJ; Iglewski BH
    Rev Infect Dis; 1983; 5 Suppl 5():S992-7. PubMed ID: 6419321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exotoxin production by clinical isolates of pseudomonas aeruginosa.
    Pollack M; Taylor NS; Callahan LT
    Infect Immun; 1977 Mar; 15(3):776-80. PubMed ID: 404244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.